Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd
(NQ:
CYTO
)
0.9574
-0.0526 (-5.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altamira Therapeutics Ltd
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stocks That Hit 52-Week Lows On Thursday
July 21, 2022
During Thursday's trading, 50 companies set new 52-week lows.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 20, 2022
Investors ready to start trading early this morning will want to check out the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance
July 19, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday.
Via
Benzinga
Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study
May 20, 2022
Via
Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
July 20, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and...
Via
Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
July 19, 2022
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue...
Via
Benzinga
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal
July 12, 2022
HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Topics
Death
Exposures
Death
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
June 29, 2022
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
June 27, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Tuesday
June 28, 2022
On Tuesday, 87 companies hit new 52-week lows.
Via
Benzinga
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
June 23, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
June 28, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
June 27, 2022
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
Via
Benzinga
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo
June 13, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
June 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray
June 08, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia
May 31, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
May 23, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
May 20, 2022
Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
May 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Issues Shareholder Letter
May 18, 2022
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd....
From
Altamira Therapeutics
Via
AccessWire
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
April 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
April 12, 2022
- Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. - Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver -...
From
Altamira Therapeutics
Via
AccessWire
Why Altamira Therapeutics Stock Is Soaring
April 11, 2022
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading higher Monday after the company announced a peer-reviewed publication on positive in vitro data with its Bentrio...
Via
Benzinga
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
April 11, 2022
Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant - Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics FY 2021 Earnings Conference Call On April 12, 2022 At 08:00 AM ET
April 04, 2022
Altamira Therapeutics (NASDAQ:CYTO) will host a conference call at 08:00 AM ET on April 12, 2022, to discuss FY 2021 earnings results. How to Attend Altamira Therapeutics (CYTO) Conference Call Follow...
Via
Benzinga
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
April 04, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it...
From
Altamira Therapeutics
Via
AccessWire
Topics
Earnings
Exposures
Financial
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
March 15, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
95 Biggest Movers From Friday
March 14, 2022
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9....
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.